Genmab AS (GMAB)
NASDAQ · Healthcare · Biotechnology
Genmab AS is a Healthcare company with a market capitalization of $16.04B and a trailing P/E ratio of 19.8.
5-Year Price History
Latest Annual Financials · FY ending December 31, 2025 · in DKK
Recent Quarterly Earnings (EPS)
| Quarter | Reported | Actual EPS | Estimate | Surprise |
|---|---|---|---|---|
| Q1 2026 | May 7, 2026 | $0.13 | $0.19 | -31.6% |
| Q4 2025 | February 17, 2026 | $0.21 | $0.37 | -43.2% |
| Q3 2025 | November 6, 2025 | $0.65 | $0.45 | +44.4% |
| Q2 2025 | August 7, 2025 | $0.54 | $0.34 | +58.8% |
| Q1 2025 | May 8, 2025 | $0.31 | $0.20 | +55.0% |
| Q4 2024 | February 12, 2025 | $0.84 | $0.28 | +200.0% |
Other Biotechnology Stocks
Frequently Asked Questions
What is Genmab AS's market cap?
As of June 29, 2026, Genmab AS (GMAB) has a market capitalization of $16.04B.
What is Genmab AS's P/E ratio?
Genmab AS trades at a trailing price-to-earnings (P/E) ratio of 19.8. Its forward P/E is 15.6.
Does Genmab AS pay a dividend?
Genmab AS does not currently pay a dividend.
What sector is GMAB in?
Genmab AS is in the Healthcare sector, specifically the Biotechnology industry.
What was Genmab AS's revenue?
In its latest reported fiscal year (ending December 31, 2025), Genmab AS reported revenue of 3.72B DKK and net income of 963.76M DKK.
Ask your own questions about GMAB
Try mrmarket.ai freeData as of June 29, 2026. Figures are sourced from company filings and market data and may be delayed or revised. For informational purposes only — not investment advice.